1.9.1 Drugs affecting biliary composition and flow

Ursodeoxycholic Acid
  • Tablets 150mg, 250mg, 300mg (£18.00 = 60 x 250mg tablets)
  • Oral suspension sugar free 250mg in 5ml (£26.98 = 250ml)

Indications and dose

  • Dissolution of gallstones
    • 8–12mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
  • Primary biliary cirrhosis
    • 12–16mg/kg daily in 3 divided doses for 3 months, then 12–16mg/kg once daily at bedtime
Obeticholic acid
  • Tablets 5mg, 10mg


  1. NICE TA443 Obeticholic acid for treating primary biliary cholangitis (April 2017) (NHS England Commissioned)
  • Hard capsules 200 micrograms, 400 micrograms, 600 micrograms, 1,200 micrograms


  1. NICE HST17: Odevixibat (Bylvay) is recommended, within its marketing authorisation, as an option for treating progressive familial intrahepatic cholestasis (PFIC) in people 6 months and older (February 2022). It is recommended only if the company provides odevixibat according to the commercial arrangement.


Home > Formulary > Chapters > 1. Gastrointestinal > 1.9 Drugs affecting intestinal secretions > 1.9.1 Drugs affecting biliary composition and flow


  • First line
  • Second line
  • Specialist
  • Hospital